Pathalys inks development deal with Abingworth company, raising $150M

Pathalys Pharma, a private biotech co-founded by Japanese VC Catalys Pacific and DaVita Venture Group in late 2020 to focus on chronic kidney disease, announced Wednesday morning it reached a deal with Launch Therapeutics to advance two Phase III trials for a drug designed to treat a parathyroid condition for...

Click to view original post